Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
Selective Serotonin Reuptake Inhibitors (SSRIs) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Selective Serotonin Reuptake Inhibitors (SSRIs) market is projected to reach US$ 6118 million in 2034, increasing from US$ 4788 million in 2022, with the CAGR of 3.5% during the period of 2024 to 2034. Demand from Depression and Anxiety and panic disorder are the major drivers for the industry.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Selective Serotonin Reuptake Inhibitors (SSRIs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Depression
Anxiety and panic disorder
Other mental conditions
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Selective Serotonin Reuptake Inhibitors (SSRIs) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Selective Serotonin Reuptake Inhibitors (SSRIs) introduction, etc. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Selective Serotonin Reuptake Inhibitors (SSRIs) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Selective Serotonin Reuptake Inhibitors (SSRIs) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Selective Serotonin Reuptake Inhibitors (SSRIs) market is projected to reach US$ 6118 million in 2034, increasing from US$ 4788 million in 2022, with the CAGR of 3.5% during the period of 2024 to 2034. Demand from Depression and Anxiety and panic disorder are the major drivers for the industry.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Selective Serotonin Reuptake Inhibitors (SSRIs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Segment by Application
Depression
Anxiety and panic disorder
Other mental conditions
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Selective Serotonin Reuptake Inhibitors (SSRIs) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Selective Serotonin Reuptake Inhibitors (SSRIs) introduction, etc. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Selective Serotonin Reuptake Inhibitors (SSRIs) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices